Perigon Wealth Management LLC Grows Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Perigon Wealth Management LLC raised its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 1.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,474 shares of the company’s stock after purchasing an additional 26 shares during the quarter. Perigon Wealth Management LLC’s holdings in IDEXX Laboratories were worth $632,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Berkshire Bank raised its holdings in IDEXX Laboratories by 5.4% during the fourth quarter. Berkshire Bank now owns 1,553 shares of the company’s stock worth $642,000 after purchasing an additional 80 shares in the last quarter. Union Bancaire Privee UBP SA purchased a new position in shares of IDEXX Laboratories in the 4th quarter valued at about $1,544,000. E Fund Management Hong Kong Co. Ltd. lifted its position in shares of IDEXX Laboratories by 182.8% during the 4th quarter. E Fund Management Hong Kong Co. Ltd. now owns 164 shares of the company’s stock valued at $68,000 after acquiring an additional 106 shares during the period. Empirical Financial Services LLC d.b.a. Empirical Wealth Management raised its holdings in IDEXX Laboratories by 44.5% during the fourth quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 610 shares of the company’s stock worth $252,000 after purchasing an additional 188 shares during the last quarter. Finally, Marshall Financial Group LLC boosted its position in shares of IDEXX Laboratories by 5.9% in the 4th quarter. Marshall Financial Group LLC now owns 1,996 shares of the company’s stock worth $825,000 after buying an additional 112 shares in the last quarter. 87.84% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, Director Sophie V. Vandebroek sold 344 shares of the firm’s stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $420.44, for a total value of $144,631.36. Following the transaction, the director now owns 905 shares in the company, valued at approximately $380,498.20. This trade represents a 27.54 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 2.11% of the company’s stock.

IDEXX Laboratories Trading Down 0.5 %

Shares of IDXX stock opened at $422.05 on Friday. IDEXX Laboratories, Inc. has a 1-year low of $398.50 and a 1-year high of $583.39. The firm’s 50-day simple moving average is $424.02 and its 200-day simple moving average is $454.59. The firm has a market cap of $34.56 billion, a P/E ratio of 40.70, a PEG ratio of 3.60 and a beta of 1.36. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.42 and a quick ratio of 1.03.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Thursday, October 31st. The company reported $2.80 earnings per share for the quarter, beating analysts’ consensus estimates of $2.69 by $0.11. The company had revenue of $975.50 million for the quarter, compared to analyst estimates of $980.32 million. IDEXX Laboratories had a net margin of 22.53% and a return on equity of 55.42%. IDEXX Laboratories’s revenue for the quarter was up 6.6% on a year-over-year basis. During the same quarter last year, the business earned $2.53 EPS. As a group, equities analysts forecast that IDEXX Laboratories, Inc. will post 10.44 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the stock. Barclays dropped their price objective on shares of IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating for the company in a research note on Monday, November 4th. Leerink Partners began coverage on IDEXX Laboratories in a research report on Monday, December 2nd. They issued an “outperform” rating and a $500.00 price objective on the stock. Morgan Stanley dropped their price objective on IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating for the company in a research report on Wednesday. JPMorgan Chase & Co. reduced their target price on shares of IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating on the stock in a report on Friday, October 11th. Finally, Leerink Partnrs upgraded shares of IDEXX Laboratories to a “strong-buy” rating in a report on Monday, December 2nd. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $517.29.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.